New Batches of Ranibizumab Biosimilar Safe, Effective New Batches of Ranibizumab Biosimilar Safe, Effective
Razumab, an Indian biosimilar for ranibizumab, appears to have overcome the high incidence of inflammation with a new manufacturing process, report investigators.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 15, 2016 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Ranibizumab T & amp;E cost effective for wet AMD in UK
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - August 1, 2016 Category: Drugs & Pharmacology Source Type: news

Doc's Dilemma: Lucentis or Avastin?
(MedPage Today) -- A physician weighs the risks and benefits (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - July 28, 2016 Category: American Health Source Type: news

Eye drug safety: the impact of a Cochrane Review comparing two treatments for macular degeneration
For more than 20 years, Cochrane has produced systematic reviews of primary research in human health care and health policy. We are internationally recognized as the highest standard in evidence-based healthcare resources.The fourth video in the Cochrane Making a Difference series focuses on the Cochrane Review 'Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration', published in September 2014 from the Cochrane Eyes & Vision Group. The review found that the systemic safety of bevacizumab for macular degeneration appears to be similar to that of ranibizumab - an important co...
Source: Cochrane News and Events - July 1, 2016 Category: Information Technology Authors: nowens at cochrane.org Source Type: news

Aflibercept, ranibizumab are not cost effective in DME
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 1, 2016 Category: Drugs & Pharmacology Source Type: news

Industry Incentives May Drive Pricier Anti-VEGF Drug UseIndustry Incentives May Drive Pricier Anti-VEGF Drug Use
Ophthalmologists with the most and largest payments had highest rates of injection with aflibercept and ranibizumab. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 23, 2016 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Two Expensive Diabetic Macular Edema Drugs Not Cost-effectiveTwo Expensive Diabetic Macular Edema Drugs Not Cost-effective
Anti-VEGF medicines aflibercept and ranibizumab would have to drop in price by 69% and 80%, respectively, to be worth the societal cost compared with bevacizumab, a new study has found. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 9, 2016 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

High-priced drugs used to treat diabetic macular edema not cost-effective
The anti-vascular endothelial growth factor drugs ranibizumab and aflibercept, used to treat vision loss from diabetic macular edema (DME), and approximately 20 to 30 times more expensive than bevacizumab, are not cost-effective for treatment of DME compared to bevacizumab unless their prices decrease substantially, according to a study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 9, 2016 Category: Science Source Type: news

Newer Drugs Helping Older People With Eye Disease
FRIDAY, May 20, 2016 -- New medications are boosting quality of life for many older people with age-related macular degeneration (AMD), a new study indicates. The drugs Avastin and Lucentis have significantly increased the number of people with AMD... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 20, 2016 Category: Journals (General) Source Type: news

Long-term benefits of age-related macular degeneration treatments
A 5-year follow-up study confirmed the long-term benefits of using the drugs Avastin and Lucentis to treat age-related macular degeneration. (Source: NIH Research Matters from the National Institutes of Health (NIH))
Source: NIH Research Matters from the National Institutes of Health (NIH) - May 10, 2016 Category: Consumer Health News Source Type: news

Age-related macular degeneration before and after the era of anti-VEGF drugs
NIH-funded study of Avastin and Lucentis examines their effects at five years. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - May 3, 2016 Category: American Health Source Type: news

Many With Wet AMD Need Ranibizumab Retreatment Even After Year-Long PauseMany With Wet AMD Need Ranibizumab Retreatment Even After Year-Long Pause
Retreatment with ranibizumab is necessary for up to a third of neovascular age-related macular degeneration (AMD) patients who are treatment-free for one year, new research shows. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 27, 2016 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Delayed Visual Improvements in AMD Continue With Ranibizumab TreatmentDelayed Visual Improvements in AMD Continue With Ranibizumab Treatment
Visual improvements in patients with neovascular age-related macular degeneration (AMD) treated with ranibizumab continue after macular edema resolves, researchers report. Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - March 30, 2016 Category: Opthalmology Tags: Ophthalmology News Source Type: news

Aflibercept for Macular Edema Secondary to Central RVOAflibercept for Macular Edema Secondary to Central RVO
Aflibercept may be an effective therapeutic option for macular edema due to central retinal vein occlusion that did not respond to treatment with bevacizumab or ranibizumab. Eye (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 25, 2016 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news

Aflibercept Best in Diabetics With Bad Baseline Vision? Aflibercept Best in Diabetics With Bad Baseline Vision?
Final results from a trial comparing aflibercept, bevacizumab, and ranibizumab in diabetic macular edema confirm all three drugs are similar, but aflibercept is best in those with worse baseline vision, says lead researcher. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - March 1, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

DME Drugs Equally Effective at 2 Years
(MedPage Today) -- But more adverse events seen with Lucentis versus Eylea (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 29, 2016 Category: Cardiology Source Type: news

Eylea outperforms Avastin for diabetic macular edema with moderate or worse vision loss
NIH-funded clinical trial shows Eylea, Avastin, and Lucentis perform similarly when vision loss is mild. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - February 29, 2016 Category: American Health Source Type: news

Study Compares Drugs for Common Diabetic Eye Disease
MONDAY, Feb. 29, 2016 -- People with diabetes are at risk for blurred vision or even a loss of vision from a condition called macular edema. Three drugs for the disease -- Avastin, Eylea and Lucentis -- vary widely in price, but new research... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 29, 2016 Category: Journals (General) Source Type: news

Long-term Outcomes of Ranibizumab for Neovascular AMDLong-term Outcomes of Ranibizumab for Neovascular AMD
What is the long-term outlook for patients receiving ranibizumab injections for previously untreated neovascular AMD? The British Journal of Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 25, 2016 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news

Ranibizumab for the Treatment of Wet AMDRanibizumab for the Treatment of Wet AMD
Ranibizumab for wet AMD has shown success in clinical trials, but are those same results achieved in real-world clinical practice? Eye (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - February 25, 2016 Category: Opthalmology Tags: Ophthalmology Journal Article Source Type: news

Eylea Outperforms Avastin for Diabetic Macular Edema with Moderate or Worse Vision Loss
A two-year clinical trial that compared three drugs for diabetic macular edema (DME) found that gains in vision were greater for participants receiving the drug Eylea (aflibercept) than for those receiving Avastin (bevacizumab), but only among participants starting treatment with 20/50 or worse vision. Gains after two years were about the same for Eylea and Lucentis (ranibizumab), contrary to year-one results from the study, which showed Eylea with a clear advantage. Language English (Source: News from NEI)
Source: News from NEI - February 25, 2016 Category: Opthalmology Authors: Jason Source Type: news

Diabetic Vision Loss Medication May Promote Return to DrivingDiabetic Vision Loss Medication May Promote Return to Driving
After a year of treatment with the drug ranibizumab (Lucentis), some people with vision loss due to diabetes regain their confidence to drive and have vision good enough to do so, according to a new study. Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - November 30, 2015 Category: Opthalmology Tags: Diabetes & Endocrinology News Source Type: news

Diabetic vision loss medication may promote return to driving
(Reuters Health) - After a year of treatment with the drug ranibizumab (Lucentis), some people with vision loss due to diabetes regain their confidence to drive and have vision good enough to do so, according to a new study. (Source: Reuters: Health)
Source: Reuters: Health - November 26, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

New treatment options, better hope of preventing vision loss from diabetes
This National Diabetes Month, there is some good news for people with eye complications from diabetes. A network of researchers has found that the drug Lucentis (ranibizumab) can be highly effective for treating proliferative diabetic retinopathy, an eye disease that can occur as a complication of diabetes. The researchers say this is the first major advance in therapy in 40 years. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 19, 2015 Category: Science Source Type: news

New Treatment Options, Better Hope of Preventing Vision Loss from Diabetes
This National Diabetes Month, there is some good news for people with eye complications from diabetes. Earlier this month, a network of researchers supported by the National Eye Institute (NEI) found that the drug Lucentis (ranibizumab) can be highly effective for treating proliferative diabetic retinopathy, an eye disease that can occur as a complication of diabetes. The researchers, part of the Diabetic Retinopathy Clinical Research Network, say this is the first major advance in therapy in 40 years. (Source: News from NEI)
Source: News from NEI - November 19, 2015 Category: Opthalmology Authors: Jason Source Type: news

Squalamine Boosts Anti-VEGF Effect in Macular DegenerationSqualamine Boosts Anti-VEGF Effect in Macular Degeneration
The addition of squalamine lactate to ranibizumab did not reduce the number of injections in patients with neovascular age-related macular degeneration, but it did improve visual acuity. Medscape Medical News (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - November 17, 2015 Category: Opthalmology Tags: Ophthalmology News Source Type: news

Lucentis Found Effective for Diabetic Retinopathy (CME/CE)
(MedPage Today) -- Could be first new treatment for diabetic retinopathy in many years (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 17, 2015 Category: Cardiology Source Type: news

Ranibizumab found effective against diabetic retinopathy
(Johns Hopkins Medicine) In a randomized clinical trial of more than 300 participants, researchers from Johns Hopkins and elsewhere have found that ranibizumab -- a drug most commonly used to treat retinal swelling in people with diabetes -- is an effective alternative to laser therapy for treating the most severe, potentially blinding form of diabetic retinal disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 17, 2015 Category: Global & Universal Source Type: news

Lucentis effective for proliferative diabetic retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - November 16, 2015 Category: American Health Source Type: news

Drug Lucentis May Fight Diabetic Eye Disease
Title: Drug Lucentis May Fight Diabetic Eye DiseaseCategory: Health NewsCreated: 11/13/2015 12:00:00 AMLast Editorial Review: 11/16/2015 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - November 16, 2015 Category: Endocrinology Source Type: news

Ranibizumab Deemed Major Advance for Diabetic Retinopathy Ranibizumab Deemed Major Advance for Diabetic Retinopathy
Ranibizumab was noninferior to panretinal photocoagulation for visual acuity in patients with proliferative diabetic retinopathy, according to 2-year results of the Protocol S Study. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 15, 2015 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Injection instead of laser may be viable treatment option for diabetic retinopathy
Among patients with proliferative diabetic retinopathy, treatment with an injection in the eye of the drug ranibizumab resulted in visual acuity that was not worse than panretinal photocoagulation at two years, according to a study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 15, 2015 Category: Science Source Type: news

Drug Lucentis May Fight Diabetic Eye Disease
Government-funded study finds injected medicine beats laser therapy for form of retinopathy (Source: WebMD Health)
Source: WebMD Health - November 14, 2015 Category: Consumer Health News Source Type: news

Diabetic blindness could be reversed with eye injection
Injecting the drug ranibizumab into the eyes of diabetics improved their sight and prevented further deterioration (Source: Telegraph Health)
Source: Telegraph Health - November 14, 2015 Category: Consumer Health News Tags: injection ranibizumab blind drugs blindness diabetes Source Type: news

Drug Lucentis May Fight Diabetic Eye Disease
Government-funded study finds injected medicine beats laser therapy for form of retinopathy Source: HealthDay Related MedlinePlus Pages: Diabetic Eye Problems, Eye Diseases, Medicines (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - November 14, 2015 Category: Consumer Health News Source Type: news

Lucentis Effective for Proliferative Diabetic Retinopathy
A clinical trial funded by the National Institutes of Health has found that the drug ranibizumab (Lucentis) is highly effective in treating proliferative diabetic retinopathy. The trial, conducted by the Diabetic Retinopathy Clinical Research Network (DRCR.net) compared Lucentis with a type of laser therapy called panretinal or scatter photocoagulation, which has remained the gold standard for proliferative diabetic retinopathy since the mid-1970s. The findings demonstrate the first major therapy advance in nearly 40 years. Language English (Source: News from NEI)
Source: News from NEI - November 11, 2015 Category: Opthalmology Authors: Jason Source Type: news

Eylea vs Lucentis for Treatment-Naive Neovascular AMDEylea vs Lucentis for Treatment-Naive Neovascular AMD
A new study compares outcomes between these two drugs in previously untreated patients with neovascular AMD. How do they stack up? BMC Ophthalmology (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - October 5, 2015 Category: Opthalmology Tags: Ophthalmology Journal Article Source Type: news

Anti-VEGF Therapy Before Steroids for Retinal Vein OcclusionAnti-VEGF Therapy Before Steroids for Retinal Vein Occlusion
Aflibercept and ranibizumab should be the first-line options in the treatment of central retinal vein occlusion, according to one small study. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 21, 2015 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

'Encouraging' Real-life Data on Ranibizumab in Wet AMD'Encouraging' Real-life Data on Ranibizumab in Wet AMD
Most patients with age-related macular degeneration (AMD) in a 'real-life' study maintained their vision or continued to improve after 5 years of treatment with ranibizumab. Medscape Medical News (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - September 19, 2015 Category: Opthalmology Tags: Ophthalmology News Source Type: news

Effectiveness and Costs of Bevacizumab vs Ranibizumab in DMEEffectiveness and Costs of Bevacizumab vs Ranibizumab in DME
A new head-to-head trial compares the efficacy and economic value of these two anti-VEGF agents for DME. Which one has the edge? BMC Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 7, 2015 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news

Intas cuts Razumab supplies after adverse eye reactions
Razumab, a biosimilar of Genentech’s Lucentis, was launched in June at about 25 per cent cheaper than the innovator drug marketed by Novartis. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 21, 2015 Category: Pharmaceuticals Source Type: news

Ranibizumab for Neovascular AMD in Eyes With Good VisionRanibizumab for Neovascular AMD in Eyes With Good Vision
Starting ranibizumab treatment for neovascular AMD in eyes with good baseline visual acuity may provide additional benefits to visual outcomes. The British Journal of Ophthalmology (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - August 20, 2015 Category: Opthalmology Tags: Ophthalmology Journal Article Source Type: news

Endophthalmitis Risk No Greater With Avastin Than Lucentis Endophthalmitis Risk No Greater With Avastin Than Lucentis
FDA-proposed restrictions on the ophthalmic use of bevacizumab through compounding pharmacies may be unnecessary, researchers find. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 17, 2015 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Eye Infection Risk Similar for Avastin, Lucentis Injections (CME/CE)
(MedPage Today) -- Calls FDA guidance limiting ophthalmic bevacizumab compounding into question (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - August 14, 2015 Category: Geriatrics Source Type: news

Bevacizumab vs Ranibizumab for Macular Edema Due to BRVOBevacizumab vs Ranibizumab for Macular Edema Due to BRVO
How does treatment between these two anti-VEGF agents compare in terms of visual acuity and central retinal thickness outcomes? The British Journal of Ophthalmology (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - July 23, 2015 Category: Opthalmology Tags: Ophthalmology Journal Article Source Type: news

Squalamine Shows Promise in Retinal Vein OcclusionSqualamine Shows Promise in Retinal Vein Occlusion
The combination of topical squalamine and intravitreal ranibizumab appears to boost visual acuity more rapidly than ranibizumab alone in patients with retinal vein occlusion, a small study shows. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 20, 2015 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Drug Dosages Questioned in Diabetic Macular Edema TrialDrug Dosages Questioned in Diabetic Macular Edema Trial
Experts wonder whether increased doses might eliminate the advantages seen with aflibercept over bevacizumab and ranibizumab in a diabetic macular edema trial. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 18, 2015 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Ranibizumab Effective for Pigment Epithelial DetachmentRanibizumab Effective for Pigment Epithelial Detachment
Detachments of any size can effectively be treated with low-dose ranibizumab in patients with neovascular age-related macular degeneration, new research shows. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 18, 2015 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Dexamethasone Implant as Adjunct Therapy for Wet AMDDexamethasone Implant as Adjunct Therapy for Wet AMD
Are there benefits to augmenting ranibizumab therapy with dexamethasone intravitreal implant treatment in patients with refractory wet AMD? The British Journal of Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 29, 2015 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news

Switching Anti-VEGF Agents in Treatment-Resistant Wet AMDSwitching Anti-VEGF Agents in Treatment-Resistant Wet AMD
Is aflibercept an effective therapeutic alternative for cases of wet AMD resistant to ranibizumab? BMC Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 12, 2015 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news